未治疗海绵窦脑膜瘤的体积生长速率
本研究回顾37例未治疗海绵窦脑膜瘤患者的166次MR影像,中位随访33.8个月,通过体积测量评估自然生长速率。估计年体积增长率为23.3%(95% CI 10.2%-38.0%,p < 0.001),相当于体积倍增时间3.3年(95% CI 2.1-7.1年),生长速率与年龄或性别无显著关系。
要点
- 未治疗海绵窦脑膜瘤年体积增长率约23.3%,体积倍增时间约3.3年。
- 65%肿瘤在观察期内体积增长超过20%,中位绝对增长率为41%。
- 生长速率与年龄(p=0.09)或性别(p=0.78)无显著关系。
核心结论
- 未治疗海绵窦脑膜瘤存在可测量的体积生长,年增长率23.3%,体积倍增时间3.3年。
- 了解其自然生长史有助于优化患者咨询和个体化管理。
研究设计与样本
- 回顾性分析37例未治疗海绵窦脑膜瘤患者,共166次MR影像,平均每例4.5次(范围2-13次)。
- 影像采集于2004年5月至2019年9月,平均随访45.9个月(中位33.8,范围2.8-136.9个月),纳入所有干预前影像。
主要发现
- 估计年体积增长率为23.3%(95% CI 10.2%-38.0%,p < 0.001),体积倍增时间3.3年(95% CI 2.1-7.1年)。
- 生长速率与患者年龄(p=0.09)或性别(p=0.78)无显著关系。
- 中位绝对增长率为41%(范围-1%至1793%)。
- 以观察期内增长大于20%定义生长,65%的肿瘤显示生长。
- 37例中,22%(8例)无生长(年增长<5%,倍增时间>13.9年),32%(12例)慢速生长(年增长5%-20%,倍增时间3.5-13.9年),38%(14例)中速生长(年增长20%-100%,倍增时间0.7-3.5年),8%快速生长(年增长>100%,倍增时间<0.7年)。
关键数值与推荐
- 生长定义:观察期内体积增加大于20%。
- 生长分类:无生长(年增长<5%,倍增时间>13.9年);慢速(年增长5%-20%,倍增时间3.5-13.9年);中速(年增长20%-100%,倍增时间0.7-3.5年);快速(年增长>100%,倍增时间<0.7年)。
临床怎么用
- 对于未治疗的海绵窦脑膜瘤,可参考年增长率23.3%和倍增时间3.3年进行随访规划和患者咨询。
- 根据个体生长速率分类(无、慢、中、快)制定个体化随访间隔和治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Meningiomas that arise primarily within the cavernous sinus are often believed to be more indolent in their growth pattern. Despite this perceived growth pattern, disabling symptoms can arise even with small tumors. While research has been done on cavernous sinus meningiomas (CSMs) and their treatment, very little is known about their natural growth rates. With a better understanding of the growth rate of CSM, patient treatment and guidance can be can optimized and individualized. The goal of this study was to determine volumetric growth rates of untreated CSMs. METHODS: Thirty-seven patients with 166 MR images obtained between May 2004 and September 2019 were reviewed, with a range of 2-13 MR images per patient (average of 4.5 MR images per patient). These scans were obtained over an average follow-up period of 45.9 months (median 33.8, range 2.8-136.9 months). All imaging prior to any intervention was included in this analysis. Volumetric measurements were performed and assessed over time. RESULTS: The estimated volumetric growth rate was 23.3% per year (95% CI 10.2%-38.0%, p < 0.001), which is equivalent to an estimated volume doubling time (VDT) of 3.3 years (95% CI 2.1-7.1 years). There was no significant relationship between growth rate and patient age (p = 0.09) or between growth rate and patient sex (p = 0.78). The median absolute growth rate was 41% with a range of -1% to 1793%. With a definition of "growth" as an increase of greater than 20% during the observed period, 65% of tumors demonstrated growth within their observation interval. Growth rates for each tumor were calculated and tumors were segmented based on growth rate. Of 37 patients, 22% (8) demonstrated no growth (< 5% annual growth, equivalent to a VDT > 13.9 years), 32% (12) were designated as slow growth (annual growth rate 5%-20%, VDT 3.5-13.9 years), 38% (14) were found to have medium growth (annual growth rate 20%-100%, VDT 0.7-3.5 years), and 8% were considered fast growing (annual growth rate > 100%, VDT < 0.7 years). CONCLUSIONS: This study evaluated CSM volumetric growth rates. A deeper understanding of the natural history of untreated CSMs allows for better counseling and management of patients.
引用
- Benjamin CG, Schnurman Z, Ashayeri K, et al. Volumetric growth rates of untreated cavernous sinus meningiomas. J Neurosurg. 2021. PMID: 34416713. doi:10.3171/2021.2.JNS203485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。